These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 32345624

  • 1. Predictive value of integrated 18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer.
    Umeda Y, Morikawa M, Anzai M, Ameshima S, Kadowaki M, Waseda Y, Shigemi H, Tsujikawa T, Kiyono Y, Okazawa H, Ishizuka T.
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345624
    [Abstract] [Full Text] [Related]

  • 2. Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.
    Kaira K, Higuchi T, Naruse I, Arisaka Y, Tokue A, Altan B, Suda S, Mogi A, Shimizu K, Sunaga N, Hisada T, Kitano S, Obinata H, Yokobori T, Mori K, Nishiyama M, Tsushima Y, Asao T.
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):56-66. PubMed ID: 28828507
    [Abstract] [Full Text] [Related]

  • 3. Prognostic Value of the Volumetric Parameters of Dual-Time-Point 18F-FDG PET/CT in Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy.
    Okazaki E, Seura H, Hasegawa Y, Okamura T, Fukuda H.
    AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
    Usmanij EA, de Geus-Oei LF, Troost EG, Peters-Bax L, van der Heijden EH, Kaanders JH, Oyen WJ, Schuurbiers OC, Bussink J.
    J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P, Janvary ZL, Coucke P, Jodogne S, Bernard C, Hatt M, Visvikis D, Jansen N, Duysinx B, Hustinx R.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer.
    Avallone A, Aloj L, Pecori B, Caracò C, De Stefano A, Tatangelo F, Silvestro L, Granata V, Bianco F, Romano C, Di Gennaro F, Budillon A, Petrillo A, Muto P, Botti G, Delrio P, Lastoria S.
    J Nucl Med; 2019 Nov; 60(11):1560-1568. PubMed ID: 30877175
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
    Huang YS, Chen JL, Chen JY, Lee YF, Huang JY, Kuo SH, Yen RF, Chang YC.
    Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.